SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001714899-18-000013
Filing Date
2018-11-01
Accepted
2018-11-01 06:08:01
Documents
3
Period of Report
2018-10-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K a8-k11x1x18.htm 8-K 44656
2 EXHIBIT 99.1 ex991pressrelease11118.htm EX-99.1 17213
3 logoasjpega05.jpg GRAPHIC 30236
  Complete submission text file 0001714899-18-000013.txt   104710
Mailing Address 151 OYSTER POINT BLVD. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38311 | Film No.: 181151871
SIC: 2836 Biological Products, (No Diagnostic Substances)
Assistant Director 1